Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The forefront of ovarian cancer therapy: update on PARP inhibitors

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. L-Lysine increased the cytotoxicity effect of doxorubicin in MDA-MB-231 and MDA-MB-468 breast cancer cell lines

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

  2. TSGA10 and H2AX competition over binding HIF-1 in breast cancer

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  • M R Mirza
  • R L Coleman
  • A González-Martín
  • K N Moore
  • N Colombo
  • I Ray-Coquard
  • S Pignata
Vis graf over relationer

BACKGROUND: In recurrent ovarian cancer, poly(ADP-ribose) polymerase (PARP)-inhibiting agents have transformed the treatment of platinum-sensitive disease. New data support use of PARP inhibitors earlier in the treatment algorithm.

DESIGN: We review results from recent phase III trials evaluating PARP inhibitors as treatment and/or maintenance therapy for patients with newly diagnosed ovarian cancer. We discuss the efficacy and safety of these agents in the all-comer and biomarker-selected populations studied in clinical trials, and compare the strengths and limitations of the various trial designs. We also consider priorities for future research, with a particular focus on patient selection and future regimens for populations with high unmet need.

RESULTS: Four phase III trials (SOLO-1, PAOLA-1/ENGOT-OV25, PRIMA/ENGOT-OV26 and VELIA/GOG-3005) demonstrated remarkable improvements in progression-free survival with PARP inhibitor therapy (olaparib, niraparib or veliparib) for newly diagnosed ovarian cancer. Differences in trial design (treatment and/or maintenance setting; single agent or combination; bevacizumab or no bevacizumab), patient selection (surgical outcome, biomarker eligibility, prognosis) and primary analysis population (intention-to-treat, BRCA mutated or homologous recombination deficiency positive) affect the conclusions that can be drawn from these trials. Overall survival data are pending and there is limited experience regarding long-term safety.

CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.

OriginalsprogEngelsk
TidsskriftAnnals of Oncology
Vol/bind31
Udgave nummer9
Sider (fra-til)1148-1159
Antal sider12
ISSN0923-7534
DOI
StatusUdgivet - sep. 2020

Bibliografisk note

Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.

ID: 60987070